



Hungarian Association of Rheumatologists
H-1023 Budapest, Ürömi út 56. • Telefax: (36-1) 336-0464
Information e-mail: titkarsag@mre.hu

CECR 2010

8th Central European Congress of Rheumatology

23rd–25th September 2010, Sopron, Hungary
Liszt Ferenc Conference and Cultural Center

FINAL PROGRAMME

PROGRAMME OUTLINE

September 23rd (Thursday)

08.30–09.00	Opening ceremony
09.00–10.00	Pathogenesis of rheumatoid arthritis
10.00–10.30	Coffee break
10.30–11.30	New treatment modalities in systemic inflammatory rheumatic diseases
11.30–12.30	Perspectives in rheumatoid arthritis and spondyloarthritis – Treatment needs and therapeutic options. Satellite symposium: MSD
12.30–13.30	Lunch-time
13.30–14.30	New trends in spondylarthropathies
14.30–15.30	Treating AS as soon as possible. Satellite symposium: Pfizer
15.30–16.00	Coffee break
16.00–17.00	Traditional DMARDs versus biologics in the management of rheumatoid arthritis
17.00–18.30	Guided sightseeing in the downtown of Sopron
19.00	Dance and music from Central Europe Performance by the Honvéd Art Ensemble in the Petőfi Theatre, Sopron
20.30	Welcome reception at the Liszt Ferenc Conference Center

September 24th (Friday)

08.30–09.30	News in progressive systemic sclerosis
09.30–10.30	Optimising patient pathways in RA. Satellite symposium: Pfizer
10.30–11.00	Coffee break
11.00–12.00	Anti-TNFs in the forefront of biologic treatment in RA. Satellite symposium: Abbott
12.00–13.00	Lunch-time
13.00–14.00	Disease activity and functional measurements in rheumatology
14.00–15.00	The RANK ligand inhibitor – fracture protection throughout the skeleton. Satellite symposium: Amgen&GlaxoSmithKline
15.00–15.30	Coffee break
15.30–16.30	Endocrine parameters in rheumatic diseases
16.30	Piano concert from the compositions of Ferenc Liszt at the Conference Centre
20.00	Buffet dinner and rock and roll evening in the Sports Hall of Sopron

September 25th (Saturday)

08.30–9.30	Poster session – authors at posters
09.30–10.30	Efficacy of teriparatide in the treatment of severe osteoporosis. Satellite symposium: Eli Lilly
10.30–11.00	Coffee break
11.00–12.00	New worlds in RA management. Satellite symposium: Roche
12.00	Closing of the CECR
12.00–13.00	Lunch-time
13.00	Opening of the Congress of the Hungarian Association of Rheumatologists
20.00	Beer festival and wine tasting



CECR 2010

8th Central European Congress of Rheumatology

23rd–25th September 2010, Sopron, Hungary
Liszt Ferenc Conference and Cultural Center

FINAL PROGRAMME

■ Exclusive major sponsors



Abbott

A Promise for Life



Lilly



■ WELCOME ADDRESS

Dear Colleagues and Friends,

On behalf of the organizers I'd like to welcome most cordially all of you to the 8th Central European Congress of Rheumatology (CECR) in Sopron, Hungary.

Not only rheumatologists from the six organizing countries (Austria, Czech Republic, Hungary, Poland, Slovakia, Slovenia) but also specialists and general practitioners interested in musculoskeletal conditions from different parts of Europe will be active participants of this meeting.

The story of the CECR started in Piešťany where the first congress took place in 1996. It was followed by Warsaw (1998), Bratislava (2000), Baden bei Wien (2002), Budapest (2004), Bled (2006), and Prague (2008). The passed 14 years, the number of attendees and the scientific level of the events justified the importance of this biennial congress. Beside the regional scientific collaboration the event has always been an ideal opportunity for the experience of Central European feeling and creative activity.

This year the charming, historical, Western Hungarian town, Sopron acts as host to the congress. In the scientific programme distinguished specialists present state of the art lectures and other oral papers. More than 150 abstracts have been submitted from 25 countries in order to discuss hot topics of molecular and clinical rheumatology. Leading pharmaceutical companies are present with their exhibition booth and six of them (Abbott, Amgen & GlaxoSmithKline, Eli Lilly, MSD, Pfizer and Roche) have the possibility to organize satellite symposia. The social programmes, the special atmosphere of the town and the delicious Hungarian wines and foods will also help us to make this meeting a memorable event. Many thanks the major sponsors for their support making possible the high-standard conditions.

The organizers have spared no time to ensure that this meeting will be an exciting and useful experience for all of you. Your attendance and precious contribution to the success of the meeting are highly appreciated.

We wish you a pleasant stay in Sopron.

Best personal regards

Sopron, September 23, 2010.

Prof. Dr. Gyula Poór

Chairman of the Congress
President, Hungarian Association of
Rheumatologists

ORGANIZATION AND GENERAL INFORMATION

Patron

Prof. Dr. Miklós Réthelyi
Minister, Ministry of National Resources

Congress venue

Liszt Ferenc Conference and Cultural Center
H-9400 Sopron, Liszt Ferenc u. 1.,
Tel: +36 99 517 500, www.prokultura.hu

Congress Chairman and Scientific Programme Coordinator

Prof. Dr. Gyula Poór
President, Hungarian Association of Rheumatologists

Congress Committee

The Congress Committee includes the current presidents of rheumatology societies of the six organizing countries.
Burkhard Leeb (Austria), Boris Lestan (Slovenia), Gyula Poór (Hungary), Jozef Rovensky (Slovakia), Witold Tlustochowicz (Poland) and Jiří Venkovský (Czech Republic)

Local Organizing and Scientific Committee

Gyula Poór, György Hittner, László Czirják, Pál Géher, Zoltán Szekanecz, Emese Kiss, Judit Ortutay and the Board of the Hungarian Association of Rheumatologists

Official language

English

On site registration fees

Registration fee covers receipt of all the congress documents (final programme, abstract book, etc.), participation in all scientific sessions and social events, coffee breaks and access to commercial exhibition. On site payment modality is cash only.

Participants from organizing countries (Austria, Czech Republic, Hungary, Poland, Slovakia, Slovenia)	€ 300
Other countries	€ 400
Trainees, health professionals, accompanying persons	€ 150
One day participation	€ 200

Responsibility and insurance

The organizers cannot accept any responsibility for personal injuries, or loss, or damage to private property. It is recommended that participants and accompanying persons possess travel and additional insurance of their own.

Currency and payment

The Hungarian currency is Forint (HUF). International credit cards are accepted in hotels, restaurants and major shops.

Certification of attendance

A certificate of attendance will be included in the Congress bag.

Hungarian Association of Rheumatologists

E-mail: titkarsag@mre.hu
Website: www.mre.hu

■ SCIENTIFIC INFORMATION

Main topics

- Pathogenesis, early diagnostics and management of inflammatory musculoskeletal conditions
- Disease activity measurements
- DMARDs and biologicals
- Endocrine parameters in rheumatic diseases
- Primary and secondary osteoporosis
- Orphan diseases
- Miscellaneous

Type of presentations

The scientific programme includes different thematic programme blocks, satellite symposia and manned poster presentations. Leading experts from Europe have been invited to present state of the art lectures. Additional oral presenters were selected from authors of the submitted abstracts.

■ SCIENTIFIC PROGRAMME

September 23rd (Thursday)

8.30–09.00 Opening ceremony

9.00–10.00 Pathogenesis of rheumatoid arthritis

Chairmen: Włodzimierz Maslinski and Zoltán Szekanecz

O1 Synovial biopsy for the assessment of rheumatoid arthritis and the action of biologics (15')
Paul Peter Tak

University of Amsterdam, The Netherlands

O2 Bone marrow in the pathogenesis of rheumatoid arthritis (15')
Włodzimierz Maslinski, Weronika Rudnicka, Ewa Warnawin, Anna Radzikowska, Monika Prochorec, Tomasz Burakowski, Magdalena Chorazy-Massalska, Ewa Kontny, Paweł Małdyk
Institute of Rheumatology, Warsaw, Poland

O3 Cytokine activities in rheumatoid arthritis pathogenesis (15')
Iain McInnes
University of Glasgow, Scotland

O4 B-cells and their targeting in rheumatoid arthritis (10')
Péter Szodoray
University of Oslo, Norway

Discussion

10.00–10.30 Coffee break

10.30–11.30 New treatment modalities in systemic inflammatory rheumatic diseases

Chairmen: Steffen Gay and Jiří Vencovský

O5 Novel strategies for the treatment of arthritis (15')
Steffen Gay
University Hospital, Zurich, Switzerland

O6 Advances in the therapy of myositis (15')
Jiří Vencovský
Institute of Rheumatology, Prague, Czech Republic

O7 New possibilities in the treatment of vasculitis (12')
Vladimir Tesar
Charles University, Prague, Czech Republic

O8 New prospective biologicals in the treatment of rheumatoid arthritis (12')
Ladislav Šenolt
Institute of Rheumatology, Prague, Czech Republic

Discussion

11.30–12.30 Perspectives in rheumatoid arthritis and spondyloarthritis – Treatment needs and therapeutic options

Satellite symposium: MSD

Chairman: László Hodinka

OS1 Rapid radiographic progression and therapy choice in rheumatoid arthritis
Peter C. Taylor
Imperial College London, United Kingdom

OS2 Golimumab: An effective and convenient therapy to address the needs of patients with rheumatoid arthritis
Iain McInnes
University of Glasgow, Scotland

OS3 Spondyloarthritis: Many manifestations of one disease – a multidisciplinary approach to management
Joachim Sieper
Charité University Berlin, Germany

Discussion

12.30–13.30 Lunch-time

13.30–14.30 New trends in spondylarthropathies

Chairmen: Karel Pavelka and Pál Géher

O9 Pathogenetic background of spondylarthritis (15')
Joachim Sieper
Charité University Berlin, Germany

O10 New approaches in the diagnostics and monitoring of spondyloarthritis (15')
Maxime Dougados
René Descartes University, Paris, France

O11 Long-term efficacy and safety of anti-TNF-therapies in ankylosing spondylitis; experiences from nation-wide registry ATTRA (15')
Karel Pavelka
Institute of Rheumatology, Prague, Czech Republic

O12 Vascular diseases in ankylosing spondylitis (10')
Sándor Szántó, Nóra Bodnár, Rudolf Gesztesy, Ádám Kemény-Beke, Zoltán Szekanecz
University of Debrecen, Hungary

Discussion

Awarding of the honorary membership of the Hungarian Association of Rheumatologists

14.30–15.30 Treating ankylosing spondylitis as soon as possible

Satellite symposium: Pfizer

Chairman: Gyula Poór

OS4 The need for early intervention in spondyloarthritis
Maxime Dougados
René Descartes University, Paris, France

OS5 Efficacy of etanercept in the treatment of ankylosing spondylitis
Tamás Palotai
Special Hospital for Rheumatology of the Regional Health Insurance of Lower Austria, Baden, Austria

OS6 Evaluation of radiological progression in the management of ankylosing spondylitis

Joachim Sieper

Charité University Berlin, Germany

Discussion

15.30–16.00 Coffee break

16.00–17.00 Traditional DMARDs versus biologics in the management of rheumatoid arthritis

Chairmen: Josef Smolen and Witold Tlustochowicz

O13 Do we need traditional DMARDs in the biologic era? (15')

Witold Tlustochowicz

Military Institute of Medicine, Warsaw, Poland

O14 How to use different biologicals for optimal treatment of patients with rheumatoid arthritis? (15')

Josef Smolen

Medical University, Vienna, Austria

O15 DMARD and biological treatment modalities in childhood (15')

Emese Kiss

National Institute of Rheumatology and Physiotherapy,
Semmelweis University, Budapest, Hungary

O16 Enthesitis: Evolving concepts and sonographic evaluation (10')

Péter Bálint, Péter Mandl, Katalin Ács, Éva Ruzicska

National Institute of Rheumatology and Physiotherapy, Budapest,
Hungary

 **September 24th (Friday)**

08.30–09.30 News in progressive systemic sclerosis

Chairmen: Boris Lestan and László Czirják

O17 Incidence of scleroderma spectrum disorders in Slovenia (15')

Alenka Šipek-Dolničar

University Medical Centre, Ljubljana, Slovenia

O18 Clinical importance of nailfold capillaroscopy in the early diagnosis of systemic sclerosis (15')

Maurizio Cutolo

University of Genoa, Italy

O19 Lung involvement in systemic sclerosis (12')

Nemanja Damjanov

Institute of Rheumatology Belgrade, Serbia

O20 Emergency states in systemic sclerosis (12')

Luc Mouton

Hopital Cochin, Rene Descartes University, Paris, France

Discussion

Awarding of the honorary membership of the Hungarian Association of Rheumatologists

09.30–10.30 Optimising patient pathways in rheumatoid arthritis

Satellite symposium: Pfizer

Chairman: Karel Pavelka

OS7 Towards optimal management of the rheumatoid arthritis patient

Paul Peter Tak

University of Amsterdam, The Netherlands

OS8 Clinical results with etanercept in early rheumatoid arthritis

Tom Huizinga

Leiden University Medical Center, The Netherlands

OS9 Ten years of TNF-blockers for treating rheumatoid arthritis:
What have the registries taught us?
Emilio Martin Mola
Hospital University La Paz, Madrid, Spain

Discussion

10.30–11.00 Coffee break

11.00–12.00 Anti-TNFs in the forefront of biologic treatment in rheumatoid arthritis
Satellite symposium: Abbott
Chairman: Gyula Poór

OS10 Access to innovative rheumatoid arthritis treatments in EU
Gyula Poór
National Institute of Rheumatology and Physiotherapy,
Semmelweis University, Budapest, Hungary

OS11 Classification and management of rheumatoid arthritis – the 2010 news
Josef Smolen
Medical University, Vienna, Austria

OS12 Treat to target – implement today for tomorrow
Karel Pavelka
Institute of Rheumatology, Prague, Czech Republic

OS13 Importance of ultrasonography in early detection and monitoring of rheumatoid arthritis patients
Walter Grassi
University of Ancona, Italy

Discussion

12.00–13.00 Lunch-time

13.00–14.00 Disease activity and functional measurements in rheumatology

Chairmen: Piet van Riel and Burkhard Leeb

O21 Composite measures (15')
Piet van Riel

Radboud University Nijmegen Medical Centre, The Netherlands

O22 Patient related outcomes in routine monitoring of rheumatoid arthritis patients (15')
Burkhard F. Leeb
Center for Rheumatology, Stockerau, Austria

O23 Development of remission and minimal disease activity cut-points for the juvenile arthritis disease activity score (JADAS) (12')
Angelo Ravelli, Consolaro Alessandro
University of Genoa, Italy

O24 Outcome measures in the rehabilitation of musculoskeletal conditions (12')
Ernst Wagner, Tamás Palotai
Special Hospital for Rheumatology of the Regional Health Insurance of Lower Austria, Baden, Austria

Discussion

14.00–15.00 The RANK ligand inhibitor – fracture protection throughout the skeleton

Satellite symposium: Amgen & GlaxoSmithKline

Chairmen: Socrates Papapoulos and Gyula Poór

OS14 The diverse role of the RANK/RANKL/OPG system
Gyula Poór
National Institute of Rheumatology and Physiotherapy,
Semmelweis University, Budapest, Hungary

OS15 Bone strength – role of trabecular and cortical bone
Péter Lakatos
Semmelweis University, Budapest, Hungary

OS16 Effect of denosumab treatment of bone turnover markers and BMD

Pavel Horak

Palacky University, Olomouc, Czech Republic

OS17 Clinical evidence for antifracture protection of denosumab

Socrates Papapoulos

Leiden University Medical Center, The Netherlands

15.00–15.30 Coffee break

15.30–16.30 Endocrine parameters in rheumatic diseases

Chairmen: Maurizio Cutolo and Jozef Rovenský

O25 Neuroendocrine-immune network in rheumatic diseases (15')

Maurizio Cutolo

University of Genoa, Italy

O26 Klinefelter's syndrome, Turner syndrome and rheumatic diseases (15')

Jozef Rovenský

National Institute of Rheumatic Diseases, Piešťany, Slovakia

O27 Hypothalamic-pituitary-adrenal function in rheumatoid arthritis (15')

Richard Imrich

Center for Molecular Medicine, Bratislava, Slovakia

O28 The presence and function of nicotinic acetylcholine receptors on osteoclasts, and their effect on osteoclastogenesis (10')

Péter Mandl^{1,2}, Silvia Hayer², Despoina Sykoutri², Gyula Poór¹,

Josef Smolen², Kurt Redlich²

¹National Institute of Rheumatology, Budapest, Hungary,

²University of Vienna, Austria

Discussion

 **September 25th (Saturday)**

08.30–09.30 Poster session – authors at posters

P1 Major histocompatibility complex class I. chain-related gene A: Risk and protective alleles in systemic lupus erythematosus pathogenesis

Marketa Fojtíková¹, Peter Novota¹, Pavlina Cejkova², Dana Tegzova¹, Satu Pesickova¹, Karel Pavelka¹, Marie Cerna²

¹Institute of Rheumatology, ²Charles University, Prague, Czech Republic

P2 Rheumatoid arthritis and prolactin: Association with disease activity and joint damage

Marketa Fojtíková¹, Jana Tomasová Studýnková¹, Maria Filková¹, Zdeňka Lacinová², Jindřiška Gatterová¹, Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹

¹Institute of Rheumatology, ²Charles University and General University Hospital in Prague, Czech Republic

P3 Lipid peroxidation and antioxidant enzyme activities in patients with systemic lupus erythematosus

Attila Kovács¹, Do Huy Quai², Aranka László², Ilona Varga²

¹Hospital of Hungarian State Railways, Szolnok, ²University of Szeged, Hungary

P4 Lupus nephritis: The therapeutic aspects

Teuta Backa, Alma Idrizi, Myftar Barbullushi, Argjend Tafaj, Alketa Koroshi

UHC Mother Teresa, Tirana, Albania

P5 Flaccide hypokalemic paralysis in a patient with primary Sjögren's syndrome

Teuta Backa, Alma Idrizi, Myftar Barbullushi, Kliti Hoti

UHC Mother Teresa, Tirana, Albania

- P6 Vascular endothelial growth factor and basic fibroblast growth factor in systemic lupus erythematosus with Jaccoud's arthropathy
Zbynek Hrcir, Marcela Drahosova, Ctirad Andrys, Petr Bradna, Tomas Soukup, Jan Toms
University Hospital, Hradec Králové, Czech Republic
- P7 Vascular endothelial growth factor and epidermal growth factor in patients with systemic sclerosis and systemic lupus erythematosus
Radim Becvar¹, Ivana Putova¹, Michal Tomcik¹, Simona Skacelova¹, Dana Tegzova¹, Radka Svobodova¹, Jiri Stork², Petr Zatloukal³, Alena Zatloukalova³
¹Institute of Rheumatology, ²General Teaching Hospital, ³Clinic of Pneumology and Thoracic Surgery, Prague, Czech Republic
- P8 Prevalence, incidence and survival of diffuse systemic sclerosis in Dalmatia county, Croatia
Mislav Radić, Dušanka Martinović Kaliterna, Josipa Radić, Damir Fabijanić, Vedran Kovačić
University Hospital Split, Croatia
- P9 Impact of metacarpophalangeal and proximal interphalangeal joints flexion contractures on disability and health-related quality of life in systemic sclerosis
Mislav Radić, Dušanka Martinović Kaliterna, Josipa Radić
University Hospital Split, Croatia
- P10 Peripheral neuropathy in systemic sclerosis patients
Diana Vučina, Dušanka Martinović Kaliterna, Mislav Radić
University Hospital Split, Croatia
- P11 Systemic sclerosis – clinical and immunological features of 211 patients of Slovak population
Jozef Lukáč, Ol'ga Lukáčová, Jozef Rovenský, František Máliš, Peter Poprac, Alena Tuchyňová, Roman Stančík, Darina Kozáková, Karol Bitter
National Institute of Rheumatic Diseases, Piešťany, Slovakia

- P12 Altered cellular immunity in diffuse cutaneous systemic sclerosis
Gábor Papp¹, Ildikó Fanny Horváth¹, Sándor Baráth¹, Edit Gyimesi¹, Péter Szodoray², Margit Zeher¹
¹University of Debrecen, Hungary, ²Rikshospitalet University of Oslo, Norway
- P13 Evaluation of the cardiopulmonary status in systemic sclerosis patients with ergospirometry and stress echocardiography
Daniella Hulló¹, Gergely Ágoston¹, János Varga¹, Imre Lajkó¹, Ágnes Milassin¹, Attila Somfay¹, Albert Varga¹, Attila Pálinskás², László Kovács¹
¹University of Szeged, ²Erzsébet Hospital, Hódmezővásárhely, Hungary
- P14 Selected risk factors for coronary heart disease in patients with psoriatic arthritis, who were treated in the rheumatology clinic in Wrocław between 2008–2009
Renata Sokolik, Dominik Samotij, Agata Sebastian, Arkadiusz Chlebicki, Piotr Wiland
Rheumatology Clinic, Wrocław, Poland
- P15 ¹⁶⁶Holmium-phytate-radiosynoviorthesis in rheumatoid arthritis. Five years clinical results. Phase III. prospective study
Margit Szentesi, Pál Géher
Polyclinic of the Hospitaller Brothers of St. John of God, Budapest, Hungary
- P16 Regulation of CD3 expression on human T-lymphocytes
György Nagy, Barbara Érsek, Zoltán Wiener, Melinda Rácz, Edit Buzás, Viktor Molnár, Pál Géher, András Falus
Semmelweis University, Budapest, Hungary

P17 The impact of the anti-cyclic-citrullinated peptide antibody status in the management of patients with early rheumatoid arthritis in Hungary: Results from an interim analysis

Péter Juhász¹, Katalin Dankó², Katalin Fazekas³, Ramóna Gaál¹, Judit Korda¹, Hajnalka Laczkó⁴, Nóra Nusser⁵, Katalin Seregely⁶, János Szász⁷, Eszter Tóvári⁸, Edit Verecke¹, Orsolya Nagy⁹, Gyula Poór¹
¹National Institute of Rheumatology and Physiotherapy, Budapest,
²University of Debrecen, ³Szent Ferenc Hospital, Miskolc, ⁴Vaszary Kolos Hospital, Esztergom, ⁵Zsigmondy Vilmos Hospital, Harkány,
⁶Bács-Kiskun County Hospital, Kecskemét, ⁷I. Rheumatology Clinic, Székesfehérvár, ⁸Integrated Health Care Institution of Pécs,
⁹Abbott Laboraties (Hungary) Ltd., Budapest, Hungary

P18 Correlation between clinical manifestation and immune-genetic determinants at patients with psoriatic arthritis in Republic of Moldova

Liliana Groppa, Liudmila Gonta, Eugeniu Russu
State Medical and Pharmaceutical University "Nicolae Testemitanu", Kishinau, Moldova

P19 Assessment of clinical efficiency of tocilizumab in disease evolution of patients from Moldova with rheumatoid arthritis

Liliana Groppa, Daniela Cepoi-Bulgac, Eugeniu Russu, Laura Vremis, Hellis Osama
State Medical and Pharmaceutical University "Nicolae Testemitanu", Kishinau, Moldova

P20 Influence of glucose level control in blood on evolution of inflammatory joint syndrome at patients with a diabetes mellitus type 2.

Liliana Groppa, Lia Chislari, Eugeniu Russu, Zinaida Anestiadi
State Medical and Pharmaceutical University "Nicolae Testemitanu", Kishinau, Moldova

P21 Research of a bone metabolism at patients with diabetes mellitus type 2.

Liliana Groppa, Lia Chislari, Eugeniu Russu, Zinaida Anestiadi
State Medical and Pharmaceutical University "Nicolae Testemitanu", Kishinau, Moldova

P22 The role of Th17 cells in spondylitis ankylopoetica

Attila Balog¹, Balázs Szalay², László Kovács¹, Daniella Hulló¹, Barna Vásárhelyi²

¹University of Szeged, ²Semmelweis University, Budapest, Hungary

P23 Frequency of myostitis-specific and myositis-associated autoantibodies in the serum of patients with idiopathic inflammatory myopathies

Katalin Dankó¹, Melinda Vincze¹, Judit Tumpek¹, Lászlóné Szőllősi¹, Peter J. Charles²

¹University of Debrecen, Hungary, ²Kennedy Institute, Imperial College London, United Kingdom

P24 Anti-Pm-Scl autoantibody positivity in patients with idiopathic inflammatory myopathy

Andrea Váncsa¹, Peter J. Charles², Júlia Németh³, Andrea Ponyi⁴, Judit Tumpek¹, Melinda Vincze¹, Katalin Dankó¹

¹University of Debrecen, Hungary, ²Kennedy Institute, Imperial College London, United Kingdom, ³National Institute of Health, Budapest, ⁴Semmelweis University, Budapest, Hungary

P25 Association of idiopathic inflammatory myositis and myasthenia gravis

Anna Bazsó¹, Anna Polgár¹, Edit Verecke¹, Mária Judit Molnár², Gyula Poór¹, Emese Kiss¹

¹National Institute of Rheumatology and Physiotherapy, ²Semmelweis University, Budapest, Hungary

P26 Anti muscarinic receptor-3 autoantibodies in secondary Sjögren's syndrome

Magdolna Deák, Nóra Árgyelán, Attila Balog, Daniella Hulló, Gyula Pokorný, Mária Kiss, Gábor Tóth, László Kovács
University of Szeged, Hungary

P27 The immune-modulating role of vitamin A, D and E in the pathogenesis of primary Sjögren's syndrome

Ildikó Fanny Horváth, Gábor Papp, Sándor Baráth, Péter Szodoray, Margit Zeher
University of Debrecen, Hungary

- P28 Thalidomide in the treatment of Behcet's syndrome in a 16 year old girl
Elena Koskova¹, Daniela Salatová², Stanislava Blažíčková¹, Vladimír Bošák¹, Jozef Rovensky¹
¹National Institute of Rheumatic Diseases, Piešťany, ²Pediatric Rheumatology Outpatient's Department, Žilina, Slovakia
- P29 Investigation of connective tissue diseases depending on serologic markers in young women who have somatisation disorders order and carried out systemic interrogation in details
Ozgur Tanrıverdi
Safak Health Group Goztepe Hospital, Istanbul, Turkey
- P30 The effect of the different doses of alfacalcidol on regulatory T-cells in patients with undifferentiated connective tissue disease
Éva Zöld, Sándor Baráth, János Kappelmayer, László Csáthy, Edit Gyimesi, Ágota Hajas, Margit Zeher, Gyula Szegedi, Edit Bodolay
University of Debrecen, Hungary
- P31 What is the minimum duration of symptoms to suspect undifferentiated arthritis?
Burkhard F. Leeb¹, Pia M. Haindl¹, Klaus P. Machold², Bernhard Rintelen¹, Manfred Herold³
¹Lower Austrian State Hospital Weinviertel Stockerau,
²Universitätsklinik III AKH Wien, ³Universitätsklinik Innsbruck, Austria
- P32 Initial therapy in patients with undifferentiated peripheral inflammatory arthritis: A systematic literature review
Burkhard F. Leeb¹, Pia M. Haindl¹, Hans Peter Brezinschek², Bernhard Rintelen¹, Gabriele Eber³
¹Lower Austrian State Hospital Weinviertel Stockerau,
²Universitätsklinik Graz, ³Rheumaklinikum Malcherhof, Baden, Austria

- P33 Optimal time to start disease modifying therapy in patients with undifferentiated peripheral arthritis: A systematic literature review and expert consensus
Burkhard F. Leeb¹, Pia M. Haindl¹, Gabriele Eber², Manfred Herold³, Bernhard Rintelen¹
¹Lower Austrian State Hospital Weinviertel Stockerau,
²Rheumaklinikum Malcherhof, Baden, ³Universitätsklinik Innsbruck, Austria
- P34 A comparison of patient questionnaires and composite indexes in routine care of rheumatoid arthritis patients
Burkhard F. Leeb, Judith Sautner, Harsono T. Mai, Pia M. Haindl, Bernhard Rintelen
Lower Austrian State Hospital Weinviertel Stockerau, Austria
- P35 Usefulness of procalcitonin measurement in differentiating between activity of systemic autoimmune disease and bacterial infection
Olga Sleglova¹, Helena Dejmeková¹, Jana Uhrova², Jaromír Belácek³
¹Institute of Rheumatology, ²Institute of Clinical Biochemistry, ³Charles University, Prague, Czech Republic
- P36 Measurement of interleukin-1-receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease
Boglárka Brágós¹, Emese Kiss², Gyula Szegedi¹, Sándor Sipka¹, Margit Zeher¹
¹University of Debrecen, ²National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P37 Involvement of specific types of laminin in glomerular basement membrane of patients with lupus nephritis and monitoring of serum levels of laminin as possible marker of organ damage
Hana Ciferska¹, Pavel Horák¹, Josef Zadrazil¹, Zuzana Hermanová², Yrjo Kontinen³, Martin Tichý¹
¹University of Olomouc, ²Faculty Hospital, Olomouc, Czech Republic, ³University of Helsinki, Finland

P38 Challenges and experiences of teaching courses of the modified Rodnan skin score assessment in systemic sclerosis
Tünde Minier¹, Ruxandra Ionescu², Simona Rednic³, Nemanja Damjanov⁴, Cecília Varjú¹, Zoltán Nagy⁵, László Czirják¹

¹University of Pécs, Hungary, ²Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania, ⁴Institute of Rheumatology Belgrade, Serbia, ⁵Szatmár-Bereg Hospital and Medical Bath, Fehérgyarmat, Hungary

P39 Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis
Tünde Minier¹, Zoltán Nagy², Zsófia Bálint¹, Helka Farkas¹, Gábor Kumánovics¹, Diána Simon¹, Cecília Varjú¹, Péter Németh¹, László Czirják¹

¹University of Pécs, ²Szatmár-Bereg Hospital and Medical Bath, Fehérgyarmat, Hungary

P40 Patient and physicians global assessment on disease activity of rheumatoid arthritis
Bernadette Rojkovich¹, András Inotai², Ágnes Mészáros², Emese Jászay¹, Katalin Imre¹, Györgyi Mészáros¹
¹Polyclinic of the Hospitaller Brothers of St. John of God, ²Semmelweis University, Budapest, Hungary

P41 The rheumatoid arthritis EULAR response criteria compared to the RADAI-5 response in daily routine
Bernhard Rintelen, Pia M. Haindl, Judith Sautner, Barbara A. Leeb, Christiane Kaspar, Burkhard F. Leeb
Lower Austrian State Hospital Weinviertel Stockerau, Austria

P42 Proposals for thresholds to express improvement and deterioration in rheumatoid arthritis patients according to the RADAI-5
Bernhard Rintelen, Judith Sautner, Christiane Kaspar, Pia M. Haindl, Barbara A. Leeb, Burkhard F. Leeb
Lower Austrian State Hospital Weinviertel Stockerau, Austria

P43 Summary findings of a systematic review of global ultrasound scores for the assessment of synovitis in rheumatoid arthritis
Péter Mandl¹, Péter V. Bálint¹, Esperanza Naredo², Richard J. Wakefield³, Maria-Antonietta D'Agostino⁵, on behalf of the OMERACT-EULAR Ultrasound Group

¹National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ²Hospital Severo Ochoa, Madrid, Spain, ³University of Leeds, Chapel Allerton Hospital, Leeds, United Kingdom, ⁴Paris-Ouest-Versailles Saint Quentin en Yvelines University, Paris, France

P44 Ultrasound for detecting abnormal effusion and synovial proliferation in the knee – which knee position is the best?
Péter Mandl¹, Lene Terslev², Wolfgang A. Schmidt³, Myriam Brossard⁴, Péter V. Bálint¹, Esperanza Naredo⁵, Richard J. Wakefield⁶, Maria-Antonietta D'Agostino⁷ on behalf of the OMERACT-EULAR Ultrasound Group

¹National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ²University of Copenhagen Hospitals at Hvidovre and Glostrup, Denmark, ³Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus, Berlin, Germany, ⁴Versailles-Saint Quentin en Yvelines University; APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France, ⁵Hospital Severo Ochoa, Madrid, Spain, ⁶University of Leeds, Chapel Allerton Hospital, Leeds, United Kingdom, ⁷Paris-Ouest-Versailles Saint Quentin en Yvelines University, Paris, France

P45 Tumor necrosis factor alpha and soluble tumor necrosis factor receptor type 1 levels comparison in blood serum in rheumatoid arthritis and ankylosing spondylitis patients
Inita Bulina¹, Daina Andersone¹, Vladimirs Lavrentjevs², Janis Arajs², Ineta Astica², Julija Zepa², Evita Sikora², Sarmite Abelite², Inta Jaunalksne²

¹Latvian University, ²Pauls Stradiņš Clinical University Hospital, Riga, Latvia

P46 Radiological particularities of joint involves in women with ankylosing spondylitis in correlation with HLA-B27 antigen
Oxana Sirbu, Liliana Groppa, Eugeniu Russu
State Medical and Pharmaceutical University “Nicolae Testemitanu”, Kishinau, Moldova

P47 Experience with the use of Quantiferon test, a novel method to detect tuberculosis, in two arthritis centers in Budapest, Hungary
István Á. Juhász¹, Judit Korda², Bernadette Rojkovich¹
¹Polyclinic of the Hospitaller Brothers of St. John of God, ²National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

P48 Experiences with tumour necrosis factor alpha inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy registry
Krisztina Sevcic¹, Ilonka Orbán¹, Valentin Brodszky², Anna Bazsó¹, Zsolt Balogh¹, Emese Kiss¹
¹National Institute of Rheumatology and Physiotherapy, ²Corvinus University, Budapest, Hungary

P49 Treatment of adult juvenile idiopathic arthritis patients with TNF-blockers and effect of switching to a second anti-TNF agent. Data from the Czech national registry
Katerina Jarosova¹, Karel Chroust², Lucie Burešová², Jiří Vencovský¹
¹Charles University Prague, ²Institute of Biostatistics and Analyses, Brno, Czech Republic

P50 Biological therapy in patients with rheumatoid arthritis (observation for longer time)
Oľga Lukáčová, Jozef Lukáč, Jozef Rovenský
National Institute of Rheumatic Diseases, Piešťany, Slovakia

P51 A long-term follow up in the Czech National Registry ATTRA: Efficacy of anti-TNF-alpha inhibitors on the quality of life in rheumatoid arthritis and ankylosing spondylitis patients
Katarína Hviščová¹, Liliana Šedová¹, Karel Chroust², Lucie Burešová², Karel Pavelka¹
¹Institute of Rheumatology Prague, ²Masaryk University, Brno, Czech Republic

P52 Assessment of fatigue in patients with ankylosing spondylitis receiving biological TNF antagonist therapy
Seçil Demirdal, Fatima Yaman, Hasan Toktas, Vural Kavuncu
Afyon Kocatepe University, School of Medicine, Afyonkarahisar, Turkey

P53 Methotrexate-naïve psoriatic arthritis patients respond rapidly to infliximab plus methotrexate therapy – results from the RESPOND trial
Helena Raffayova¹, N. Kungurov², A. Kubanova³, A. Baranaskaite⁴, A. Venalis⁵, L. Helmle⁶, E. Nasonov⁷
¹National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²Ural Dermatovenerology Institute, Jekaterinburg, Russia, ³Centra DermatoVenerology Institute, Moscow, Russia, ⁴Kaunas Medical University Hospital, Lithuania, ⁵Vilnius University Hospital, Lithuania, ⁶Schering-Plough Corp., Budapest, Hungary, ⁷Central Rheumatology Institute, Moscow, Russia

P54 Biologic therapy and pregnancy
Ilona Ujfalussy¹, Bernadette Rojkovich², Éva Koó², László Czirják³, Cecília Varjú³, Zoltán Szekanecz⁴, Katalin Nagy⁵, Ilonka Orbán⁶
¹Ministry of Defence, State Medical Centre, Budapest, ²Polyclinic of the Hospitaller Brothers of St. John of God, Budapest, ³University of Pécs, ⁴University of Debrecen, ⁵Markhot Ferenc Hospital, Eger, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

P55 TNF-alpha antagonist treatment of renal amyloidosis complicating rheumatoid arthritis. A five-year follow-up of two patients
Györgyi Mészáros¹, Kálmán Polner², Bernadette Rojkovich¹, István Á. Juhász¹
¹Polyclinic of the Hospitaller Brothers of St. John of God, ²St. Margit Hospital, Budapest, Hungary

P56 HLA-DRB1*15 is associated with very high levels of anti-cyclic citrullinated peptide antibodies and non response to infliximab in rheumatoid arthritis
Judit Laki^{1,2}, Emeli Lundström², Omri Snir², Johan Rönnelid³, Sædis Sævarsdottír², Marius Wick², Lars Alfredsson³, Lars Klareskog², Leonid Padyukov²
¹Ministry of Defence, State Medical Centre, Budapest, Hungary, ²Karolinska Institutet, Stockholm, ³Uppsala University, Sweden

- P57 On the occurrence of compelling reasons for the interruption of treatment with TNF-alpha inhibitors
Éva Lányi, Pál Géher
Polyclinic of the Hospitaller Brothers of St. John of God, Budapest, Hungary
- P58 Difficulties in the management of patients with biological therapy
Katalin Nagy, Judit Jász, Mária Pelsőczi, Eszter Deák
Markhot Ferenc Hospital, Eger, Hungary
- P59 Tocilizumab induced Tako-Tsubo cardiomyopathy in a patient with rheumatoid arthritis
Angéla Tóth¹, Ilona Márkus¹, Klára Barabás², László Krivanek², Gyula Poór¹
¹National Institute of Rheumatology and Physiotherapy, ²Health Service of First District of Budapest, Hungary
- P60 Comparison of occurrence of adverse events in patients with rheumatoid arthritis and ankylosing spondylitis treated with biologic therapy in Czech National Registry ATTRA
Šárka Forejtová¹, Hermann Mann¹, Karel Chroust², Lucie Burešová², Karel Pavelka¹
¹Institute of Rheumatology, Prague, ²Institute of Biostatistics and Analyses, Brno, Czech Republic
- P61 Acquired inhibitor to factor VIII in patient with rheumatoid arthritis previously on biologics
Katalin Imre¹, László Nemes², Bernadette Rojkovich¹
¹Polyclinic of the Hospitaller Brothers of St. John of God, ²Ministry of Defence, State Medical Centre, Budapest, Hungary
- P62 Effectiveness of leflunomide in psoriatic joint and skin disease: Results from a multinational non-interventional study of psoriatic arthritis treated with leflunomide
F. Behrens^{1,2}, K. Pavelka³, J. Štolfa³, A. Sipek-Dolnicar⁴, H. Burkhardt^{1,2}, On behalf of the OSPAL-Study Group
¹Johann Wolfgang Goethe University, Frankfurt am Main, Germany, ²Rheumazentrum Rhein-Main, Germany, ³Institute of Rheumatology, Prague, Czech Republic, ⁴University Medical Center Ljubljana, Slovenia

- P63 Association of methotrexate treatment and serum levels of Dickkopf-1 and cartilage oligomeric matrix protein in rheumatoid arthritis patients
Jerzy Swierkot, Katarzyna Gruszecka Marczynska, Agnieszka Matuszewska, Piotr Wiland
Wroclaw Medical University, Poland
- P64 Life-threatening leucopenia during methotrexate therapy of rheumatoid arthritis
Petr Bradna, Jaroslav Maly, Tomas Soukup, Alzbeta Zavrelova, Jan Toms, Oldrich Siroky, Miroslav Pecka, Dalibor Milka
Charles University Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic
- P65 Retrospective study of polymyalgia rheumatica treated with glucocorticoids plus methotrexate
Zsuzsa Schmidt, György Hittner, Gyula Poór
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P66 Sympathoneural and adrenomedullary responses to orthostasis in female patients with rheumatoid arthritis
Jozef Rovenský, Miroslav Vlcek, Adela Penesova, Martin Zlnay, Anna Scipova, Zofia Radikova, Richard Imrich
Institute of Experimental Endocrinology, Bratislava, Slovakia
- P67 Age peculiarities of bone loss in women with rheumatoid arthritis
Vladyslav Povoroznyuk, Tetyana Karasevska
Institute of Gerontology AMS, Kiev, Ukraine
- P68 Osteoporosis in patients of different age with ankylosing spondylitis
Vladyslav Povoroznyuk
Institute of Gerontology AMS, Kiev, Ukraine
- P69 Vitamin-D deficiency and insufficiency in Ukrainian population
Vladyslav Povoroznyuk, Nataliya I. Balatska, Victor Y. Muts, Tetiana Y. Solonenko, Volodymyr Vayda
Institute of Gerontology AMS, Kiev, Ukraine

P70 Effect of zolendronic acid in treatment of postmenopausal women with osteoporosis
Vladyslav V. Povoroznyuk, Natalia Grygorieva, Volodymyr Vayda, Natalia Dzerovych, Nataliya I. Balatska
Institute of Gerontology AMS, Kiev, Ukraine

P71 Prevention of osteoporosis in Northern youth
Milana Petrova N.
North-Eastern Federal University, Yakutsk, Russia

P72 The role of Vitamin-D and calcium in prevention of postmenopausal osteoporosis
Nikolov Tatjana¹, Vladimir Bobic², Branislav Bobic¹
¹Institute for Rheumatology Novi Sad, ²Pfizer H.C.P, Corporation Beograd, Serbia

P73 A ten year study of clinical fractures, changes in density, risk factors and FRAX in normal and osteopenic postmenopausal women
Csaba Kiss, Éva Ruzicska, Gyula Poór
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

P74 Evaluation of Achilles tendon and plantar fascia in diffuse idiopathic skeletal hyperostosis by ultrasound and X-ray
Csaba Kiss, Ádám Mester, Péter Mandl, Éva Ruzicska, Péter Bálint, Gyula Poór
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

P75 Quantifying of serum concentration of beta crosslaps as a factor of estimate in efficacy bisphosphonate therapy in postmenopausal women with osteoporosis
Aleksandar Jovanovski¹, Olgica Rankovic¹, Jadranka Bozovic-Jelic¹, Zoran Grujic²
¹Regional Hospital Sabac, ²Special Hospital for rheumatology Banja Koviljaca, Serbia

P76 Proposition for a national training program in musculoskeletal ultrasound in Hungary, based on available programs in Europe and in the United States
Katalin Áts, Péter Mandl, Éva Ruzicska, György Hittner, László Hodinka, Péter Bálint, Gyula Poór
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

P77 Psychosomatic status in patients with gout
Larisa Rotaru, Liliana Groppa, Elena Deseatnicova, Mircea Revenco
State Medical and Pharmaceutical University, Kishinau, Moldova

P78 Cognitive dysfunction in the Czech population of patients with systemic lupus erythematosus
Radka Svobodova¹, Marie Posmurova¹, Vera Peterova², Petr Kozelek², Ivana Putova¹, Marketa Fojtíková¹, Ctibor Dostal¹, Marta Olejarova¹
¹Institute of Rheumatology, ²Faculty Hospital of Charles University, Prague, Czech Republic

P79 Rehabilitation in rheumatology in the era of biological therapy
Márta Király, Judit Ortutay
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

P80 Inpatient rehabilitation of musculoskeletal diseases in centres of the Austrian Pension Insurance Institution – data of outcome measurement
Werner Kullich¹, Rudolf Müller²
¹LBG, Institute for Rehabilitation, Cluster Rheumatology, Balneology, Rehabilitation, Saalfelden, ²PVA – Pension Insurance Institution, Vienna, Austria

P81 Clinical characteristics of 97 patients with inflammatory myopathy
Cecília Varjú, Tünde Minier, Mónika Péter, Krisztina Parti, Gábor Kumánovics, Dániel Kehl, Tímea Berki, Diána Simon, László Czirják
University of Pécs, Hungary

- P82 Clinical characteristics of patients with immunodeficiency syndromes
Dóra Niedermayer, Gábor Kumánovics, László Czirják, Tímea Berki, Gábor Sütő
University of Pécs, Hungary
- P83 Distinct phenotypes in mixed connective tissue disease:
Subgroups and survival
Ágota Hajas¹, Péter Szodoray², Éva Zöld¹, István Csípő¹, Margit Zeher¹, Gyula Szegedi¹, Edit Bodolay¹
¹University of Debrecen, Hungary, ²University of Oslo, Norway
- P84 About Wegener's granulomatosis: Results from a single centre
Anna Polgár, Gyula Poór, Emese Kiss
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P85 Formal pathogenesis of AA amyloidosis in rheumatoid arthritis
Miklós Bély¹, Ágnes Apáthy²
¹Polyclinic of the Hospitaller Brothers of St. John of God, ²National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P86 High prevalence of amyloidosis AA in patients with adult onset Still's disease
Arkadiusz Chlebicki¹, Bożena Kowalewska¹, Eliza Roszkowska¹, Renata Wojtala², Piotr Wiland¹
¹Academic Clinical Hospital Wrocław, ²Medical University, Wrocław, Poland
- P87 Pregnancy in patients with systemic connective tissue diseases.
Results of two-years study
Dana Tegzova¹, Katerina Andelova², Ivana Kucerova²
¹Charles University, ²Institute for the Care of Mother and Child, Prague, Czech Republic
- P88 Primary Sjögren's syndrome associated liver involvement
Gábor Sütő, Tímea Berki, László Pálinskás, Péter Németh, László Czirják
University of Pécs, Hungary

- P89 Muckle Wells syndrome in a Hungarian girl
Ilonka Orbán, Krisztina Sevcic, Emese Kiss
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P90 Subcutan calcinosis: Case history
Angéla Fülöp, Bernadette Rojkovich
Polyclinic of the Hospitaller Brothers of St. John of God, Budapest, Hungary
- P91 Diagnostic difficulties and therapeutic success in a case with primary central nervous system vasculitis
Edit Verecke, Anna Bazsó, Gyula Poór, Emese Kiss
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P92 Scintigraphic, biochemical and clinical response to zoledronic acid treatment in patients with Paget's disease of bone
Judith Donáth, Gyula Poór
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- P93 Undenatured collagen type I. in the treatment of painful osteoarthritis of the knee
Roman Stančík¹, Jozef Rovenský¹, Jozef Zvarka¹, Maria Stancikova¹, Marian Hlavac², Vladimír Kubinec²
¹National Institute of Rheumatic Diseases, Piešťany, ²FDR Hospital, Banská Bystrica, Slovakia
- P94 Effect of virgin olive oil phonophoresis on exercise-induced chondromalacia
Babak Nakhostin-Roohi¹, S. Bohlooli², F. Khoshkhahesh³
¹Islamic Azad University-Ardabil Branch, ²Ardabil University of Medical Sciences, ³The University of Mohaghegh-Ardabili, Iran
- P95 Significance of some oxidant and antioxidant enzymes in fibromyalgia
Daniela Cepoi-Bulgac
State Medical and Pharmaceutical University "Nicolae Testemitanu", Kishinau, Moldova

8th Central European Congress of Rheumatology

CECR 2010, Sopron, Hungary

P96 Direct costs of chronic low back pain in Austria
Ernst Wagner
RSKA der NOEGKK, Baden, Austria

P97 National Health Service, insurance companies – from medical expert point of view
Krisztina Baraczka
Semmelweis University Budapest, Hungary

P98 Self help groups for patients with arthritis/rheumatism in Hungary
Judit Ortutay
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

09.30–10.30 Efficacy of teriparatide in the treatment of severe osteoporosis
Satellite symposium: Eli Lilly
Chairman: Juraj Payer

Welcome and objectives of the symposium
Juraj Payer
Comenius University, Bratislava, Slovakia

OS18 Anabolic therapy in the severely osteoporotic patient
Astrid Fahrleitner-Pammer
Medical University of Graz, Austria

OS19 Clinical presentation and treatment of glucocorticoid-induced osteoporosis
Willem F. Lems
Vrije University Medical Centre Amsterdam, The Netherlands

Discussion

10.30–11.00 Coffee break

8th Central European Congress of Rheumatology

CECR 2010, Sopron, Hungary

11.00–12.00 New worlds in rheumatoid arthritis management
Satellite symposium: Roche
Chairman: Gyula Poór

OS20 B-cell therapy: A “positive” direction to personalized healthcare in rheumatoid arthritis
Zoltán Szekanecz
University of Debrecen, Hungary

OS21 Tocilizumab efficacy: The science of IL-6R inhibition
László Czirják
University of Pécs, Hungary

OS22 Safety of tocilizumab in patients with rheumatoid arthritis: Analysis of long-term extension studies
Ronald van Vollenhoven
Karolinska University Stockholm, Sweden

Discussion

12.00 Closing of the CECR

12.00–13.00 Lunch-time

13.00 Opening of the Congress of the Hungarian Association of Rheumatologists

SOCIAL EVENTS**September 23rd (Thursday)**

- 17.00-18.30 Guided sightseeing in the downtown of Sopron
19.00 Dance and music from Central Europe
Performance by the Honvéd Art Ensemble in the Petőfi Theatre
(Petőfi tér 1)
20.30 Welcome reception at the Liszt Ferenc Conference Center

September 24th (Friday)

- 16.30 Piano concert from the compositions of Ferenc Liszt in the Conference Center
20.00 Buffet dinner and rock and roll evening in the Sports Hall of Sopron (Ady E. u. 5)

September 25th (Saturday)

- 20.00 Beer festival and wine tasting

HOTEL & DINING REGISTRATION**Organizer****Dekantil Ltd.**

H-1014 Budapest, Országház u. 2.
Tel.: +361-213-6222
Mobile (on the spot): +3630-508-4907
E-mail: dekantil@t-online.hu
Contact person: Krisztina Jármí

Hotel Accommodations

Hotel Fagus****	H-9400 Sopron, Ojtózi fasor 3.	+36 99 515 000	www.hotelfagus.hu
Hotel Lövér****	H-9400 Sopron, Várisi út 4.	+36 99 888 400	www.danubiushotels.hu/lover
Hotel Sopron****	H-9400 Sopron, Fövényterem utca 7.	+36 99 512 261	www.hotelsopron.hu
Best Western Pannónia Hotel****	H-9400 Sopron, Várkerület 75.	+36 99 312 180	www.pannoniahotel.com
Hunguest Hotel Szieszta***	H-9400 Sopron, Lövér körút 37.	+36 99 314 260	www.hotelszieszta.hu
Boutique Hotel Civitas***	H-9400 Sopron, Rákóczi u. 33.	+36 99 788 228	www.civitashotel.com


Bus transfers

Complimentary bus transfer will be provided between the conference center and all the hotels, which are not in walking distance (Fagus, Lövér, Sopron & Szieszta) from Thursday (23rd) morning till Sunday (26th) afternoon. The buses will run continually in the mornings approx. between 8:00-10:00, in the afternoons approx. between 16:00-20:00, then after the dinner programs approx. between 22:00-24:00.

Dining


For the participants of the congress a lunch opportunity will be offered during the congress days on the venue. The price of the buffet lunch with mineral water is 3,800 HUF per person per occasion. Lunch reservations in advance are appreciated; orders on the spot are daily limited.

Locations



1. Hotel Fagus****
H-9400 Sopron, Ojtózsi fasor 3. +36 99 515 000 www.hotelfagus.hu
2. Hotel Lövér****
H-9400 Sopron, Várisi út 4. +36 99 888 400 www.danubiushotels.hu/lover
3. Hotel Sopron****
H-9400 Sopron, Fövényverem u. 7. +36 99 512 261 www.hotelsopron.hu
4. Best Western Pannónia Hotel****
H-9400 Sopron, Várkerület 75. +36 99 312 180 www.pannoniahotel.com
5. Hunguest Hotel Szieszta***
H-9400 Sopron, Lővér körút 37. +36 99 314 260 www.hotelszieszta.hu
6. Boutique Hotel Civitas***
H-9400 Sopron, Rákóczi u. 33. +36 99 788 228 www.civitashotel.com
7. Liszt Ferenc Conference and Cultural Center
H-9400 Sopron, Liszt F. u. 1. +36 99 517 500 www.prokultura.hu
8. Petőfi Theatre
H-9400 Sopron, Petőfi tér 1. +36 99 517 517 www.prokultura.hu
9. Krasznai Ferenc Sport Hall
H-9400 Sopron, Ady Endre u. 5. +36 99 518 263

Sights at Sopron's historic oldtown



1. Fire Watch Tower, Fő tér
2. Storno Collection, Fő tér 8.
3. Exhibition on the Town's History, Fő tér 8.
4. Neolithic Lapidary, Fő tér 6.
5. Citizens' flats from the 17th–18th centuries, Fő tér 6.
6. Archaeological Exhibition, Fő tér 6.
7. Benedictine (Goat) Church, Fő tér
8. Pharmacy Museum, Fő tér 2.
9. Chapter Hall, Templom u. 1.
10. Central Museum of Mining, Templom u. 2.
11. Collection of Forestry, Templom u. 4.
12. National Lutheran Museum, Templom u. 12.
13. Medieval Synagogue, Új u. 22.
14. St. George's Church, Szent György u. 2.
15. Soproni Horváth József Collection, Hásokapu u. 2.
16. Roman Catholic Collection of Ecclesiastical Art, Orsolya tér 2.
17. Dominican Church, Széchenyi tér